Skin Boosters Market

Publisher Grand View Research

Published Mar 06, 2026

Length 108 Pages

SKU # GV21085214

Description

Skin Boosters Market Size, Share & Trends Analysis Report By Ingredient (Hyaluronic Acid, Exosomes, Polycaprolactone), By Gender (Female, Male), By End Use (Dermatology Clinics, MedSpa), By Region, And Segment Forecasts, 2026 - 2033

Skin Boosters Market Size & Trends

The global skin boosters market size was estimated at USD 1.53 billion in 2025 and is projected to reach USD 4.09 billion by 2033, growing at a CAGR of 13.1% from 2026 to 2033. Skin boosters are micro-injections of hyaluronic acid, vitamins, and minerals into the epidermis to revitalize, hydrate, and rejuvenate the skin, promoting a natural glow.

The market is expected to grow due to factors such as changing beauty standards across both developed and developing countries, greater financial accessibility to nonsurgical cosmetic procedures, increased regulatory approvals for new-age skin boosters, and rising cosmetic demand from the aging population.

The introduction of various insurance schemes for cosmetic procedures has contributed to the increase in awareness, acceptance, and growth in the skin booster market. For instance, Hamilton Fraser, the UK-based insurance company, is specifically dedicated to providing insurance for a range of aesthetic procedures, including laser treatments, dermal fillers, chemical peels, and facial treatments. Furthermore, in April 2022, AbbVie and PatientFi extended their partnership; as per the agreement, the latter firm agreed to provide financing options to AbbVie’s aesthetic product line. Such marketing agreements are expected to boost the demand for the skin booster market during the forecast period.

The growing adoption of minimally invasive cosmetic procedures is expected to drive market growth through the forecast period. The growing popularity of nonsurgical skincare treatment options is one of the primary factors responsible for an increase in the number of patients seeking skin boosters and plastic surgery services. Thus, increased demand for nonsurgical cosmetic procedures can be attributed to greater awareness of the risks and complications associated with invasive surgical procedures, including delayed healing, the risk of incision scars, and adverse reactions to anesthesia.

Increasing emphasis on professional training and skill enhancement for aesthetic practitioners also drives the growth of the skin boosters industry. Advanced injectable treatments require precision and expertise, making structured training programs essential for safe and effective outcomes. For instance, in February 2025, AbbVie announced that its division, Allergan Aesthetics, will launch three new state-of-the-art training centers in the U.S. to expand access to high-quality aesthetics education and hands-on training for providers. This initiative, led by the Allergan Medical Institute (AMI), focuses on improving clinical skills, especially in injectable treatments such as skin boosters, ensuring safer procedures and better patient outcomes. The expansion also strengthens professional training infrastructure, supporting innovation and standardization in aesthetic procedures across key U.S. regions.

Global Skin Boosters Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global skin boosters market report based on ingredient, gender, end use, and region:

Ingredient Outlook (Revenue, USD Million, 2021 - 2033)
Hyaluronic acid (HA)
Polydeoxyribonucleotides (PDRN)
Poly-L-Lactic Acid (PLLA)/ Poly-D,L-Lactic Acid (PDLLA)
Polycaprolactone (PCL)
Exosomes
Gender Outlook (Revenue, USD Million, 2021 - 2033)
Female
Male
End Use Outlook (Revenue, USD Million, 2021 - 2033)
MedSpa
Dermatology Clinics
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait

Please note The report will be delivered in 2-3 business days upon order notification.

Chapter 1. Methodology and Scope: 1.1. Market Segmentation & Scope; 1.2. Segment Definitions; 1.2.1. Ingredient; 1.2.2. Gender; 1.2.3. End Use; 1.2.4. Regional scope; 1.2.5. Estimates and forecasts timeline; 1.3. Research Methodology; 1.4. Information Procurement; 1.4.1. Purchased database; 1.4.2. GVR’s internal database; 1.4.3. Secondary sources; 1.4.4. Primary research; 1.4.5. Details of primary research; 1.4.5.1. Data for primary interviews in North America; 1.4.5.2. Data for primary interviews in Europe; 1.4.5.3. Data for primary interviews in Asia Pacific; 1.4.5.4. Data for primary interviews in Latin America; 1.4.5.5. Data for Primary interviews in MEA; 1.5. Information or Data Analysis; 1.5.1. Data analysis models; 1.6. Market Formulation & Validation; 1.7. Model Details; 1.7.1. Commodity flow analysis (Model 1); 1.7.2. Approach 1: Commodity flow approach; 1.7.3. Volume price analysis (Model 2); 1.7.4. Approach 2: Volume price analysis; 1.8. List of Secondary Sources; 1.9. List of Primary Sources; 1.10. Objectives
Chapter 2. Executive Summary: 2.1. Market Outlook; 2.2. Segment Outlook; 2.2.1. Ingredient outlook; 2.2.2. Gender outlook; 2.2.3. End Use outlook; 2.2.4. Regional outlook; 2.3. Competitive Insights
Chapter 3. Skin Boosters Market Variables, Trends & Scope: 3.1. Market Lineage Outlook; 3.1.1. Parent market outlook; 3.1.2. Related/ancillary market outlook; 3.2. Market Dynamics; 3.2.1. Market driver analysis; 3.2.1.1. Growing preference for minimally invasive procedures; 3.2.1.2. Increasing public awareness towards aesthetic procedures; 3.2.1.3. Technological advancements; 3.2.2. Market restraint analysis; 3.2.2.1. Stringent regulations & approvals; 3.2.2.2. Lack of reimbursement; 3.3. Skin Boosters Market Analysis Tools; 3.3.1. Industry Analysis - Porter’s; 3.3.1.1. Supplier power; 3.3.1.2. Buyer power; 3.3.1.3. Substitution threat; 3.3.1.4. Threat of new entrant; 3.3.1.5. Competitive rivalry; 3.3.2. PESTEL Analysis; 3.3.2.1. Political landscape; 3.3.2.2. Technological landscape; 3.3.2.3. Economic landscape
Chapter 4. Skin Boosters Market: Ingredient Estimates & Trend Analysis: 4.1. Ingredient Market Share, 2025 & 2033; 4.2. Segment Dashboard; 4.3. Global Skin Boosters Market by Ingredient Outlook; 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following; 4.4.1. Hyaluronic acid (HA); 4.4.1.1. Market estimates and forecasts, 2021 to 2033 (USD Million); 4.4.2. Polydeoxyribonucleotides (PDRN); 4.4.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million); 4.4.3. Poly-L-Lactic Acid (PLLA)/ Poly-D,L-Lactic Acid (PDLLA); 4.4.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million); 4.4.4. Polycaprolactone (PCL); 4.4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million); 4.4.5. Exosomes; 4.4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 5. Skin Boosters Market: Gender Estimates & Trend Analysis: 5.1. Gender Market Share, 2025 & 2033; 5.2. Segment Dashboard; 5.3. Global Skin Boosters Market by Gender Outlook; 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following; 5.4.1. Female; 5.4.1.1. Market estimates and forecasts, 2021 to 2033 (USD Million); 5.4.2. Male; 5.4.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 6. Skin Boosters Market: End Use Estimates & Trend Analysis: 6.1. End Use Market Share, 2025 & 2033; 6.2. Segment Dashboard; 6.3. Global Skin Boosters Market by End Use Outlook; 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following; 6.4.1. Dermatology Clinics; 6.4.1.1. Market estimates and forecasts, 2021 to 2033 (USD Million); 6.4.2. MedSpas; 6.4.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 7. Skin Boosters Market: Regional Estimates & Trend Analysis: 7.1. Regional Market Share Analysis, 2025 & 2033; 7.2. Regional Market Dashboard; 7.3. Global Regional Market Snapshot; 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033; 7.5. North America; 7.5.1. U.S.; 7.5.1.1. Key country dynamics; 7.5.1.2. Regulatory framework/ reimbursement structure; 7.5.1.3. Competitive scenario; 7.5.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million); 7.5.2. Canada; 7.5.2.1. Key country dynamics; 7.5.2.2. Regulatory framework/ reimbursement structure; 7.5.2.3. Competitive scenario; 7.5.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million); 7.5.3. Mexico; 7.5.3.1. Key country dynamics; 7.5.3.2. Regulatory framework/ reimbursement structure; 7.5.3.3. Competitive scenario; 7.5.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million); 7.6. Europe; 7.6.1. UK; 7.6.1.1. Key country dynamics; 7.6.1.2. Regulatory framework/ reimbursement structure; 7.6.1.3. Competitive scenario; 7.6.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million); 7.6.2. Germany; 7.6.2.1. Key country dynamics; 7.6.2.2. Regulatory framework/ reimbursement structure; 7.6.2.3. Competitive scenario; 7.6.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million); 7.6.3. France; 7.6.3.1. Key country dynamics; 7.6.3.2. Regulatory framework/ reimbursement structure; 7.6.3.3. Competitive scenario; 7.6.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million); 7.6.4. Italy; 7.6.4.1. Key country dynamics; 7.6.4.2. Regulatory framework/ reimbursement structure; 7.6.4.3. Competitive scenario; 7.6.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million); 7.6.5. Spain; 7.6.5.1. Key country dynamics; 7.6.5.2. Regulatory framework/ reimbursement structure; 7.6.5.3. Competitive scenario; 7.6.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million); 7.6.6. Denmark; 7.6.6.1. Key country dynamics; 7.6.6.2. Regulatory framework/ reimbursement structure; 7.6.6.3. Competitive scenario; 7.6.6.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million); 7.6.7. Sweden; 7.6.7.1. Key country dynamics; 7.6.7.2. Regulatory framework/ reimbursement structure; 7.6.7.3. Competitive scenario; 7.6.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million); 7.6.8. Norway; 7.6.8.1. Key country dynamics; 7.6.8.2. Regulatory framework/ reimbursement structure; 7.6.8.3. Competitive scenario; 7.6.8.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million); 7.7. Asia Pacific; 7.7.1. Japan; 7.7.1.1. Key country dynamics; 7.7.1.2. Regulatory framework/ reimbursement structure; 7.7.1.3. Competitive scenario; 7.7.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million); 7.7.2. China; 7.7.2.1. Key country dynamics; 7.7.2.2. Regulatory framework/ reimbursement structure; 7.7.2.3. Competitive scenario; 7.7.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million); 7.7.3. India; 7.7.3.1. Key country dynamics; 7.7.3.2. Regulatory framework/ reimbursement structure; 7.7.3.3. Competitive scenario; 7.7.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million); 7.7.4. Australia; 7.7.4.1. Key country dynamics; 7.7.4.2. Regulatory framework/ reimbursement structure; 7.7.4.3. Competitive scenario; 7.7.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million); 7.7.5. South Korea; 7.7.5.1. Key country dynamics; 7.7.5.2. Regulatory framework/ reimbursement structure; 7.7.5.3. Competitive scenario; 7.7.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million); 7.7.6. Thailand; 7.7.6.1. Key country dynamics; 7.7.6.2. Regulatory framework/ reimbursement structure; 7.7.6.3. Competitive scenario; 7.7.6.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million); 7.8. Latin America; 7.8.1. Brazil; 7.8.1.1. Key country dynamics; 7.8.1.2. Regulatory framework/ reimbursement structure; 7.8.1.3. Competitive scenario; 7.8.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million); 7.8.2. Argentina; 7.8.2.1. Key country dynamics; 7.8.2.2. Regulatory framework/ reimbursement structure; 7.8.2.3. Competitive scenario; 7.8.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million); 7.9. MEA; 7.9.1. South Africa; 7.9.1.1. Key country dynamics; 7.9.1.2. Regulatory framework/ reimbursement structure; 7.9.1.3. Competitive scenario; 7.9.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million); 7.9.2. Saudi Arabia; 7.9.2.1. Key country dynamics; 7.9.2.2. Regulatory framework/ reimbursement structure; 7.9.2.3. Competitive scenario; 7.9.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million); 7.9.3. UAE; 7.9.3.1. Key country dynamics; 7.9.3.2. Regulatory framework/ reimbursement structure; 7.9.3.3. Competitive scenario; 7.9.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million); 7.9.4. Kuwait; 7.9.4.1. Key country dynamics; 7.9.4.2. Regulatory framework/ reimbursement structure; 7.9.4.3. Competitive scenario; 7.9.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape: 8.1. Recent Developments & Impact Analysis, By Key Market Participants; 8.2. Company/Competition Categorization; 8.3. Vendor Landscape; 8.4. List of key distributors and channel partners; 8.5. Key customers; 8.6. Key company market share analysis, 2025; 8.6.1. AbbVie, Inc (Allergen); 8.6.1.1. Company overview; 8.6.1.2. Financial performance; 8.6.1.3. Product benchmarking; 8.6.1.4. Strategic initiatives; 8.6.2. Galderma; 8.6.2.1. Company overview; 8.6.2.2. Financial performance; 8.6.2.3. Product benchmarking; 8.6.2.4. Strategic initiatives; 8.6.3. Sinclair; 8.6.3.1. Company overview; 8.6.3.2. Financial performance; 8.6.3.3. Product benchmarking; 8.6.3.4. Strategic initiatives; 8.6.4. Merz Pharma; 8.6.4.1. Company overview; 8.6.4.2. Financial performance; 8.6.4.3. Product benchmarking; 8.6.4.4. Strategic initiatives; 8.6.5. Teoxane; 8.6.5.1. Company overview; 8.6.5.2. Financial performance; 8.6.5.3. Product benchmarking; 8.6.5.4. Strategic initiatives; 8.6.6. Medytox, Inc.; 8.6.6.1. Company overview; 8.6.6.2. Financial performance; 8.6.6.3. Product benchmarking; 8.6.6.4. Strategic initiatives; 8.6.7. PharmaResearch Co., Ltd.; 8.6.7.1. Company overview; 8.6.7.2. Financial performance; 8.6.7.3. Product benchmarking; 8.6.7.4. Strategic initiatives; 8.6.8. VAIM Co., Ltd; 8.6.8.1. Company overview; 8.6.8.2. Financial performance; 8.6.8.3. Product benchmarking; 8.6.8.4. Strategic initiatives; 8.6.9. Bloomage Biotechnology; 8.6.9.1. Company overview; 8.6.9.2. Financial performance; 8.6.9.3. Product benchmarking; 8.6.9.4. Strategic initiatives; 8.6.10. IBSA Farmaceutici Italia Srl; 8.6.10.1. Company overview; 8.6.10.2. Financial performance; 8.6.10.3. Product benchmarking; 8.6.10.4. Strategic initiatives; 8.6.11. Dexlevo Co., Ltd.; 8.6.11.1. Company overview; 8.6.11.2. Financial performance; 8.6.11.3. Product benchmarking; 8.6.11.4. Strategic initiatives; 8.6.12. LINKUS GLOBAL Co., Ltd.; 8.6.12.1. Company overview; 8.6.12.2. Financial performance; 8.6.12.3. Product benchmarking; 8.6.12.4. Strategic initiatives; 8.6.13. ExoCoBio Inc.; 8.6.13.1. Company overview; 8.6.13.2. Financial performance; 8.6.13.3. Product benchmarking; 8.6.13.4. Strategic initiatives

Pricing

Currency Rates

Single User Email from Publisher $5,950
Multi License Fulfilled by Publisher $6,950
Global Site License Email from Publisher $8,950

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now